Biosurgical Agents | Market Insights | Europe (Supplemental) | 2021
The COVID-19 pandemic will negatively impact the European biosurgical agent market in the short term. Once the market stabilizes, the biosurgical agent market in Europe will grow at a modest rate, primarily driven by growing surgical procedure volumes, rising awareness of the benefits of these products in surgical outcomes, and the introduction of new products with enhanced features and expanded indications. However, the European market continues to be limited by a lack of reimbursement for biosurgical agents, growing concerns over product cost, and reluctance to use products derived from human tissue among some physicians and patients, hindering the pace of market growth.
